PDGFRB and neoplasm: Sunitinib inhibits cellular signaling by targeting multiple RTKs, including platelet-derived growth factor receptor (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R), which play a role in both tumor angiogenesis and tumor cell proliferation.